In Depth: Brand-Name Drugs Feel the Squeeze in China’s Generic-Heavy Market

Multinational pharmaceutical companies are being squeezed out of the Chinese drug market as a government bulk-buying scheme favors cheaper, local products. The process is gradual, but inventories of brand-name medicines sold by the likes of Roche, Pfizer and AstraZeneca are slowly dwindling as China adds more generic versions to its procurement list and encourages doctors to prescribe them.